BioLife Solutions, a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, announced the acquisition of privately held PanTHERA CryoSolutions, a developer of novel cryopreservation solutions based on proprietary Ice Recrystallization Inhibitor (IRI) technology.
The acquisition strengthens BioLife’s position as the market leader in biopreservation, enhances its product portfolio of consumable solutions, and adds scientific capabilities to the management team.
PanTHERA completed the development and launched its first-generation IRI technology while progressing development on its next-generation molecules designed to be combined with BioLife’s line of cryopreservation products.
These next-generation formulations are expected to launch within 18 months and have the potential to provide superior cryopreservation outcomes for certain biological constructs, utilize lower concentrations of DMSO while maintaining cryopreservation efficacy, and reduce the need for liquid nitrogen used in cold chain logistics and long-term storage. And BioLife initially invested in PanTHERA in 2020 through its Bioproduction Innovation Accelerator, co-sponsored with Casdin Capital.
The acquisition highlights the success of the Bioproduction Innovation Accelerator, a strategic initiative launched by BioLife and Casdin Capital in 2019 to identify and support early-stage disruptive technologies in the bioproduction space. With initial investments in companies like Sexton Biotechnologies, the Accelerator has a proven track record of fostering early-stage innovators. Since its founding, the partnership has invested in three companies, two of which were acquired by BioLife. PanTHERA is the latest success to emerge from this initiative.
Deal details: BioLife is buying 90% of PanTHERA common shares it does not own for $9.3 million in cash and 241,355 shares of BioLife Common stock. PanTHERA’s shareholders are also eligible to receive up to $7.2 million of BioLife common stock over the next three years, contingent on achieving certain scientific and revenue milestones.
KEY QUOTES:
“This acquisition is an extension of our strategy to strengthen BioLife’s leadership position as a pure play consumables provider and enabler of advanced therapies. PanTHERA’s differentiated IRI technology enhances our core capabilities in biopreservation, and their talented scientific team shares our commitment to deliver innovative, enabling solutions for the fast-growing CGT market.”
- Roderick de Greef, BioLife Chairman and CEO
“With the addition of PanTHERA’s IRI technology and the expertise of Drs. Jason Acker and Robert Ben, we’re deepening our scientific bench and extending our technological edge. Together we are advancing the next wave of cryopreservation solutions to support our growing CGT customer base.”
- Dr. Aby Mathew, BioLife Chief Scientific Officer
“Joining BioLife is an exciting milestone for PanTHERA. We share a common vision and see enormous opportunity combining our novel IRI technology with BioLife’s ‘gold standard’ cryopreservation products. Dr. Ben and I look forward to working alongside BioLife’s world-class team to deliver next generation, high-performance solutions to the market.”
- Dr. Acker
